Exploratory identification of candidate biomarkers and molecular contributors to paclitaxel-induced peripheral neuropathy in patients with breast cancer through proteomic analysis - Scorecard - MDSpire

Exploratory identification of candidate biomarkers and molecular contributors to paclitaxel-induced peripheral neuropathy in patients with breast cancer through proteomic analysis

  • By

  • Nobuyoshi Kittaka

  • Hideaki Tahara

  • Takashi Akazawa

  • Yu Mizote

  • Takashi Kitajima

  • Keiichi Minami

  • Yurika Sugano

  • Takahiro Nakayama

  • June 16, 2026

  • 0 min

Share

Clinical Scorecard: Identification of Potential Biomarkers and Molecular Factors Associated with Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients via Proteomic Analysis

At a Glance

CategoryDetail
Condition
Key MechanismsInvolvement of neurofilament light chain (NfL) and galectin-3; oxidative stress and mitochondrial dynamics disruption related to CIPN pathophysiology.
Target Population
Care Setting

Key Highlights

  • additional_info

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • S
      • p
      • e
      • c
      • i
      • f
      • y
      • t
      • h
      • e
      • f
      • r
      • e
      • q
      • u
      • e
      • n
      • c
      • y
      • a
      • n
      • d
      • m
      • e
      • t
      • h
      • o
      • d
      • s
      • f
      • o
      • r
      • l
      • o
      • n
      • g
      • i
      • t
      • u
      • d
      • i
      • n
      • a
      • l
      • b
      • l
      • o
      • o
      • d
      • s
      • a
      • m
      • p
      • l
      • e
      • c
      • o
      • l
      • l
      • e
      • c
      • t
      • i
      • o
      • n
      • t
      • o
      • m
      • e
      • a
      • s
      • u
      • r
      • e
      • N
      • f
      • L
      • a
      • n
      • d
      • g
      • a
      • l
      • e
      • c
      • t
      • i
      • n
      • -
      • 3
      • l
      • e
      • v
      • e
      • l
      • s
      • .

      Risks

        Patient & Prescribing Data

        Patients aged ≥20 years with breast cancer receiving paclitaxel.

        Cohorts included patients starting or currently receiving paclitaxel, with a focus on those with peripheral sensory neuropathy.

        Clinical Best Practices

        • examples

        Related Resources & Content

        Original Source(s)

        Exploratory identification of candidate biomarkers and molecular contributors to paclitaxel-induced peripheral neuropathy in patients with breast cancer through proteomic analysis

        • by Nobuyoshi Kittaka, Hideaki Tahara, Takashi Akazawa, Yu Mizote, Takashi Kitajima, Keiichi Minami, Yurika Sugano, Takahiro Nakayama

        • June 16, 2026

        Related Content

        Explainable AI in breast cancer ultrasound imaging: current developments and challenges

        Risk factors for conversion to mastectomy due to positive margins in early breast cancer patients when choosing breast-conserving surgery: a retrospective cohort study

        Global research trends of TCM-based nonpharmacologic interventions in breast cancer supportive care: a bibliometric analysis (2000–2025)